Inclusion Criteria:
  -  Treatment-na√Øve or - pegIFN (or IFN), and/or Ribavirin (RBV) and/or sofosbuvir (PRS) experienced with confirmed CHC, genotypes 1, 2, 3, 4, 5, or 6, with or without compensated cirrhosis, receiving combination therapy with the all oral GLE/PIB regimen according to standard of care, international guidelines and in line with the current local label.
  -  May be enrolled up to 4 weeks after treatment initiation.
  -  Patients must voluntarily sign and date Informed Consent Form prior to inclusion into the study.
  -  Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial.
Exclusion Criteria:
  -  None.